Lung small cell

Lung, small cell (oat cell) CAV cyclophosphamide + doxorubicin (Adriamycin) + vincristine EP etoposide + cisplatin... [Pg.607]

Various, leukemia, lymphomas, lung (small cell)... [Pg.755]

Sainz and colleagues studied the presence of Nap-A in 967 lung neoplasms. The authors found that less than 5% of carcinomas of the bladder, pancreas, breast, liver, biliary tract, colon, ovary, uterus, lung squamous cell carcinoma, and lung small cell carcinoma were positive for Nap-A and that 74% of lung adenocarcinomas were positive for Nap-A versus 63% positive for... [Pg.374]

Lung small cell carcinoma (minor subset)... [Pg.375]

ImmunOreacti vity study in hitman lung small-cell carcinoma L. H. Lazarus el al. Science 219, 79 (1983). [Pg.1172]

Clinical nse These agents are used in combination drug regimens for therapy of lung (small cell), prostate, and testicular carcinoma. [Pg.482]

Physalaamin Pyr-Ala-Asp-Pro-Asn-Lys-Phe-iyr-Gly-Leu-Met-NHj, an amphibian tachykinin from the skin of the South American frog Physalaemus fus-cumaculatus [V. Erspamer et al. Experentia 20 (1964) 489-490]. P. has also been identified as a tumor-related peptide in extracts of human lung small cell carcinoma [L.H.Lazarus etal. Science 219 (1983) 79-81]. It affects blood vessels and extravascular smooth muscle, stimulates exocrine secretion, and has a distinct neurotropic effect. The C-terminal hexapeptide from P. elicits full biological response in guinea pig ileum, while the presence of the five V-terminal amino acids is necessary for full expression of sialogogic activity. Conformational studies have been reported. [J.-L. Bernier et al. Eur. J.Biochem. 142 (1984) 371-377]... [Pg.518]

V epesid) tumors small cell lung to moderate nausea and... [Pg.440]

The majority of promising drug candidates emerging from marine natural products research to date are potential cancer treatments. Six anti-cancer compounds that are either marine natural products or synthetic analogs of marine natural products have made it to clinical trials. The first of these compounds to enter clinical trials was didemnin B (43), one of a family of cyclic depsipetides isolated from the Caribbean tunicate Trididemnum solidum Didemnin B was advanced to Phase II clinical trials for treatment of small cell lung cancer, myeloma, prostate cancer, and melanoma. Unfortunately, no favorable responses were found so the compound has been withdrawn. Crude extracts of another Caribbean tunicate, Ecteinascidia turbinata, showed extremely... [Pg.74]

Suzuki, H., Takahashi, T., Kuroishi, T., Siiyama,. M., Ariyoshi, Y., Takahashi, X, and EJeda, R. rl992). p53 niurations in non-small cell lung cancer in Japan Association between mutations and smoking. Cancer Res. 52, 734-736. [Pg.344]

The usual dose consists of 1000 mg/m2 i.v. It is the most active single agent for treating pancreatic cancer, and it is used as a fust-line treatment for both pancreatic and small cell lung cancers. The dose-limiting toxicity is bone marrow suppression. [Pg.151]

Mijatovic T, Roland I, Van Quaquebeke E et al (2007) The alphal subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 212 170-9... [Pg.819]

Erlotinib (Tarceva ) competes with ATP in the HER1/EGFR ATP-binding pocket. It is used in the clinic in locally advanced or metastatic non-small cell lung cancer after failure of at least one chemotherapy regime [1, 3, 5]. [Pg.1012]

Gefitinib (Iressa ) Astra-Zeneca TKI EGFR Metastatic non-small cell lung carcinoma... [Pg.1193]

Stimuvax /BLP25 Agonist Non-small cell lung cancer Phase II clinical trials... [Pg.1211]

Breast cancer, non-small-cell lung cancer... [Pg.586]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...